title: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.
abstract: 103 patients with the diagnosis of AAF were identified from the RT/BCNU arms of 3 RTOG malignant glioma trials. Pre-treatment tumor size was less than 5 cm for 48% and greater than or equal to 5 cm for 52%, and tumor sites were frontal lobe in 55%, temporal in 25%, and parietal in 16%. Surgery consisted of biopsy for 30%, partial resection for 56%, and total resection for 14%. Extent of surgery correlated with age, with 81% of patients less than 40 undergoing partial/total resection vs. 60% of those over 40 (P = 0.019). The median survival time (MST) of patients undergoing partial/total resection was 49 mo., vs. 18 mo. for those biopsied only (P = 0.002). Patients with frontal location had longer MST than those with non-frontal lesions (MST: 49 vs. 25 mo., P = 0.047), while no survival difference was apparent by univariate analysis of tumor size. Multivariate analysis demonstrated that only younger age, frontal location, and smaller tumor size correlated significantly with extended survival. Extent of surgery was not predictive. The close correlation between young age and extensive surgery obscures the survival advantage for greater surgery seen with univariate analysis. Smaller tumor size and frontal location favorably influence outcome even when adjusted by age.
authors.affiliation: Fox Chase CC/U Philadelphia, Pennsylvania.
authors.forename: W J
authors.initials: WJ
authors.lastname: Curran
authors.forename: C B
authors.initials: CB
authors.lastname: Scott
authors.forename: J
authors.initials: J
authors.lastname: Horton
authors.forename: J S
authors.initials: JS
authors.lastname: Nelson
authors.forename: A S
authors.initials: AS
authors.lastname: Weinstein
authors.forename: D F
authors.initials: DF
authors.lastname: Nelson
authors.forename: A J
authors.initials: AJ
authors.lastname: Fischbach
authors.forename: C H
authors.initials: CH
authors.lastname: Chang
authors.forename: M
authors.initials: M
authors.lastname: Rotman
authors.forename: S O
authors.initials: SO
authors.lastname: Asbell
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001254:Astrocytoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005625:Frontal Lobe; D006801:Humans; D008875:Middle Aged; D010296:Parietal Lobe; D011379:Prognosis; D016016:Proportional Hazards Models; D016019:Survival Analysis; D013702:Temporal Lobe
chemical_list: D002330:Carmustine